2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1613

The SLE-Associated TLR7 Variant Confers Differential Gene Expression Modulated by Microrna-3148
Abstract Number: 659

The Small Molecule Activator to ACE2 Prevents the Inhibition of ACE2 Activity by Autoantibodies
Abstract Number: 1499

The Soluble Guanylate Cyclase Mediates Its Anti-Fibrotic Effects by Inhibiting TGF-β Signaling
Abstract Number: 49

The Spatial Energy Expenditure Configuration and Possible Applications in an Experimental Model of Arthritis
Abstract Number: 1962

The Specific Role of Glutaredoxin2 Isoform b (Glrx2b) in RANKL-Induced Osteoclastogenesis Through Activation of the p38-MAPK Signaling Pathway
Abstract Number: 1968

The Specific Role of Vesicle-Associated Membrane Protein-Associated Protein B/C(VapB) As a Regulator of Osteoclastogenesis Via Modulation of Phospholipase Cã(PLCã2-Ca2+-NFAT Signaling
Abstract Number: 2518

The Sphingosine-1-Phosphate Pathway Is a Key Regulator of Bone Substrate-Mediated Osteoclast Differentiation in Inflammatory Arthritis
Abstract Number: 1712

The Submaximal Heart and Pulmonary Evaluation: A Novel Noninvasive Test to Identify Pulmonary Hypertension in Patients with Systemic Sclerosis
Abstract Number: 329

The SYK Inhibitor, Fostamatinib, Administered Alone or in Combination with Methotrexate in Rat Collagen-Induced Arthritis, Reduces Bone Erosions, Biomarkers of Cartilage/Bone Destruction, and Synovial Osteoclastogenic Cytokines
Abstract Number: 2343

The Therapeutic Antibody Tregalizumab (BT-061) Induces Activation of Regulatory T Cells by Engaging a Unique CD4 Mediated Signaling That Strongly Differs From Signaling Events Induced by Standard Anti-CD4 Antibodies
Abstract Number: 2645

The Transcription Factor Mohawk Plays an Important Role for Maintaining Human Anterior Cruciate Ligament Homeostasis
Abstract Number: 2616

The Transition From Psoriasis (Ps) to Psoriatic Arthritis (PsA) Is Associated with Elevated Circulating Osteoclast Precursors (OCP) and Increased Expression of DC-STAMP
Abstract Number: 146

The Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients with Anakinra
Abstract Number: 2371

The Unmet Need in Behcet’s Disease: Most Patients Are Not in Complete Remission in the Long-Term Follow-up
Abstract Number: 1524

The Use of the International Classification of Function, Disability and Health As a Conceptual Framework for Comparison of the Content of Core Outcome Instruments with the Patient Perspective in Vasculitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].